Develop and commercialize pharmaceutical products for central nervous system (CNS) disorders. Offer treatments for epilepsy, including Trokendi XR and Oxtellar XR. Now — the numbers.
The biggest line carries real weight, but it doesn’t decide everything on its own.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
Clearly below the class average.
Growth: Sales growth trails the sector average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades 27% below its peak. The market has trimmed its expectations for the company.
The company sells $719.0M a year; the problem isn’t sales — it’s costs running above that number.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
A loss of $38.6M against $719.0M in annual sales.
The growth engine is running at low revs right now. Report-card grade: 15/100.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 24/100.
On our five-subject report card, SUPN sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: SUPN has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (56/100) says the stock isn’t cheap.